---
title: "Provision of Haemophilia Advanced Therapy Medicinal Product (ATMP) Treatment Hubs"
ocid: "ocds-h6vhtk-03b6a8"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-03b6a8"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-03b6a8.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-03b6a8.json"
source: "Find A Tender Service"
current_stage: "Tender"
buyer: "NHS ENGLAND"
published: "2023-04-12"
---

# Provision of Haemophilia Advanced Therapy Medicinal Product (ATMP) Treatment Hubs

Buyer: NHS ENGLAND  
Current stage: Tender  
OCID: ocds-h6vhtk-03b6a8

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-03b6a8)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-03b6a8.json)

## Summary

The NHS Arden and Greater East Midlands Commissioning Support Unit, on behalf of NHS England, is inviting providers to respond to an invitation to tender for the provision of Haemophilia Advanced Therapy Medicinal Product (ATMP) treatment hubs. This procurement aims to commission treatment hubs across different regions of England. The key dates for this tender include an end date amendment from 5th May 2023 to 10th May 2023.

This tender presents a significant opportunity for providers with expertise in health services to compete for contracts to deliver Haemophilia ATMP treatment hubs in various regions of England. The contracting process is currently at the tender stage. Businesses interested in providing these services must ensure compliance with the necessary qualifications and governance requirements outlined in the invitation to tender documentation.

## Notice

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf ofNHS England (referred to as the Commissioner), is inviting suitably qualified andexperienced providers to respond to this invitation to tender (ITT) exercise to commissionhaemophilia Advanced Therapy Medicinal Product (ATMP) treatment hubs.The haemophilia ATMP treatment hub allocation model is as follows:Lot 1 - One site to cover the NHS England population in the East of EnglandLot 2 - Two sites to cover the NHS England population in LondonLot 3 - One site to cover the NHS England population in the MidlandsLot 4 - One site to cover the NHS England population in the North East of England andYorkshireLot 5 - One site to cover the NHS England population in the North West of EnglandLot 6 - One site to cover the NHS England population in the South East of EnglandLot 7 - One site to cover the NHS England population in the South West of EnglandPlease note that providers must be located in the defined geographical catchment area(s) that they are interested in providing services to.

### Lot Information

Lot 1 - One site to cover the NHS England population in the East of England

The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.

Options: As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.

Lot 2 - Two sites to cover the NHS England population in London

The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.

Options: As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.

Lot 3 - One site to cover the NHS England population in the Midlands

The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.

Options: As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.

Lot 4 - One site to cover the NHS England population in the North East of Englan

The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.

Options: As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.

Lot 5 - One site to cover the NHS England population in the North West of Englan

The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.

Options: As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.

Lot 6 - One site to cover the NHS England population in the South East of Englan

The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.

Options: As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.

Lot 7 - One site to cover the NHS England population in the South West of Englan

The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.

Options: As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/010551-2023 |
| Notice type | Tender Notice |
| Procurement type | Standard |
| Procurement category | Services |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Not specified |
| All stages | Tender |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 12 Apr 2023 |
| Submission deadline | 5 May 2023 |
| Future notice date | Not specified |
| Award date | Not specified |
| Contract period | 16 Dec 2023 - 15 Dec 2031 |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | £1,000,000 |
| Lots value | £1,000,000 |
| Awards value | Not specified |
| Contracts value | Not specified |

## Status

| Field | Value |
| --- | --- |
| Tender status | Active |
| Lots status | Active |
| Awards status | Not specified |
| Contracts status | Not specified |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NHS ENGLAND |
| Locality | LEEDS |
| Post town | Leeds |
| Postcode | LS2 7UE |
| Country | England |
| ITL 1 | TLE Yorkshire and The Humber |
| ITL 2 | TLE4 West Yorkshire |
| ITL 3 | TLE42 Leeds |
| Local authority | Leeds |
| Electoral ward | Little London & Woodhouse |
| Westminster constituency | Leeds Central and Headingley |
| Delivery location | TLC North East (England), TLD North West (England), TLF East Midlands (England), TLH East (England), TLI London, TLJ South East (England), TLK South West (England) |

## CPV Codes

### Divisions

- 85 - Health and social work services

### Codes

- 85100000 - Health services

## Release History

- 12 Apr 2023 at 16:09 - TenderUpdate - Tender Notice - https://www.find-tender.service.gov.uk/Notice/010551-2023
- 28 Mar 2023 at 13:04 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/008970-2023

## Notice URLs

- https://health-family.force.com/s/Welcome
- https://www.ardengemcsu.nhs.uk/
- https://www.england.nhs.uk//

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-03b6a8. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-03b6a8.json.